PE20121685A1 - Antigeno ndv recombinante y usos del mismo - Google Patents

Antigeno ndv recombinante y usos del mismo

Info

Publication number
PE20121685A1
PE20121685A1 PE2012000888A PE2012000888A PE20121685A1 PE 20121685 A1 PE20121685 A1 PE 20121685A1 PE 2012000888 A PE2012000888 A PE 2012000888A PE 2012000888 A PE2012000888 A PE 2012000888A PE 20121685 A1 PE20121685 A1 PE 20121685A1
Authority
PE
Peru
Prior art keywords
ndv
antigen
same
polypeptide
variety
Prior art date
Application number
PE2012000888A
Other languages
English (en)
Spanish (es)
Inventor
Xuan Guo
Karolyn Marie Troupe
Bradley Feilmeier Jr
Joyce Anita Pritchard
Julio Sergio Cruz-Coy
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of PE20121685A1 publication Critical patent/PE20121685A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2012000888A 2009-12-28 2010-12-28 Antigeno ndv recombinante y usos del mismo PE20121685A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29029709P 2009-12-28 2009-12-28

Publications (1)

Publication Number Publication Date
PE20121685A1 true PE20121685A1 (es) 2012-12-28

Family

ID=44189168

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000888A PE20121685A1 (es) 2009-12-28 2010-12-28 Antigeno ndv recombinante y usos del mismo

Country Status (11)

Country Link
US (1) US10633667B2 (OSRAM)
EP (2) EP2519258B1 (OSRAM)
JP (1) JP5933451B2 (OSRAM)
KR (1) KR20120101572A (OSRAM)
CN (1) CN103260643A (OSRAM)
AR (2) AR079767A1 (OSRAM)
CA (1) CA2785653C (OSRAM)
DO (1) DOP2012000187A (OSRAM)
MX (1) MX351643B (OSRAM)
PE (1) PE20121685A1 (OSRAM)
WO (1) WO2011090708A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4130273B1 (en) * 2009-12-28 2024-06-12 Sanofi Vaccine Technologies, S.A.S. Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
US9012197B2 (en) * 2009-12-28 2015-04-21 Merial, Inc. Production of hemagglutinin-neuraminidase protein in microalgae
JP6101251B2 (ja) * 2011-05-07 2017-03-22 ラボラトリオ アヴィメキシコ エスエー ディーイー シーヴィーLaboratorio Avi−Mex, S.A. De C.V. ウイルスベクターにおける抗ｐｒｒｓ組換えワクチン
WO2013063388A1 (en) * 2011-10-28 2013-05-02 The Regents Of The University Of California Diatom-based vaccines
EP2660324A1 (en) * 2012-05-02 2013-11-06 Algenics Production of secreted therapeutic antibodies in microalgae
US20150112045A1 (en) * 2012-05-02 2015-04-23 Algenics Production of secreted therapeutic antibodies in microalgae
EP2660323A1 (en) * 2012-05-02 2013-11-06 Algenics Production of secreted therapeutic antibodies in phaeodactylum tricornutum microalgae
EP2671950A1 (de) * 2012-06-06 2013-12-11 Philipps-Universität Marburg Expression und Sekretion von rekombinanten, vollständig assemblierten Proteinkomplexen durch Mikroalgen
CN104059927B (zh) * 2014-05-09 2018-01-09 中国农业科学院生物技术研究所 鸡新城疫糖蛋白病毒抗原的制备方法及其产品
CN105567715B (zh) * 2014-10-17 2021-06-29 丰益(上海)生物技术研发中心有限公司 裂殖壶菌α-微管蛋白相关序列及其应用
EP3215602B1 (en) * 2014-11-05 2019-12-25 The Research Institute at Nationwide Children's Hospital Methods and materials for producing recombinant viruses in eukaryotic microalgae
US10196616B2 (en) * 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
CN113652406B (zh) * 2021-09-01 2023-05-02 青岛易邦生物工程有限公司 一种鸡传染性喉气管炎重组病毒株及其应用
CN119020301A (zh) * 2024-08-14 2024-11-26 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种新城疫m1n毒株及改造方法和重组疫苗制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4761373A (en) 1984-03-06 1988-08-02 Molecular Genetics, Inc. Herbicide resistance in plants
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
JPH0795952B2 (ja) 1986-01-08 1995-10-18 カルジ−ン・インコ−ポレイテツド ハロアリ−ルニトリル分解遺伝子、その使用および該遺伝子含有細胞
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5990387A (en) 1988-06-10 1999-11-23 Pioneer Hi-Bred International, Inc. Stable transformation of plant cells
NZ230375A (en) 1988-09-09 1991-07-26 Lubrizol Genetics Inc Synthetic gene encoding b. thuringiensis insecticidal protein
AU638438B2 (en) 1989-02-24 1993-07-01 Monsanto Technology Llc Synthetic plant genes and method for preparation
US5879918A (en) 1989-05-12 1999-03-09 Pioneer Hi-Bred International, Inc. Pretreatment of microprojectiles prior to using in a particle gun
US5202422A (en) 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
CA2080584C (en) 1990-04-18 2000-09-05 Marc Cornelissen Modified bacillus thuringiensis insecticidal-crystal protein genes and their expression in plant cells
US5932782A (en) 1990-11-14 1999-08-03 Pioneer Hi-Bred International, Inc. Plant transformation method using agrobacterium species adhered to microprojectiles
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
WO1992015672A1 (en) 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
TW261517B (OSRAM) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
CA2140910C (en) 1992-07-27 1999-03-23 Jeffrey A. Townsend An improved method of agrobacterium-mediated transformation of cultured soybean cells
ATE317445T1 (de) 1993-11-19 2006-02-15 Biotechnology Res & Dev Chimäre regulatorische regionen und gen - kassetten zur genexpression in pflanzen
CA2214029A1 (en) 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
WO1997004122A1 (en) 1995-07-20 1997-02-06 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US5981840A (en) 1997-01-24 1999-11-09 Pioneer Hi-Bred International, Inc. Methods for agrobacterium-mediated transformation
FR2758986B1 (fr) 1997-01-31 1999-04-30 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
US7161064B2 (en) 1997-08-12 2007-01-09 North Carolina State University Method for producing stably transformed duckweed using microprojectile bombardment
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
NZ523912A (en) 2000-07-31 2005-03-24 Biolex Inc Expression of biologically active polypeptides in duckweed
ATE352557T1 (de) 2000-11-02 2007-02-15 Intervet Int Bv Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
TWI350854B (en) 2001-04-16 2011-10-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
CA2448711A1 (en) 2001-05-30 2002-12-05 Biolex, Inc. Use of duckweed in high throughput screening
CN100435844C (zh) * 2002-08-27 2008-11-26 美国陶氏益农公司 大肠杆菌热不稳定毒素作为鸟类和家禽的佐剂的用途
AU2004235800B2 (en) * 2003-05-05 2010-02-18 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
US7132291B2 (en) * 2003-05-05 2006-11-07 Dow Agro Sciences Llc Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
EP1651265B1 (en) 2003-07-24 2008-04-23 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
US8936930B2 (en) * 2004-08-05 2015-01-20 Ben-Gurion University Of The Negev Research And Development Authority Red microalgae expressing exogenous polypeptides and methods of generating and utilizing same
JP4796787B2 (ja) 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
JP4796786B2 (ja) 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類を形質転換可能なベクター
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
ES2554703T3 (es) 2007-11-27 2015-12-22 Medicago Inc. Partículas recombinantes semejantes al virus de la influenza (VLP) producidas en plantas transgénicas que expresan hemaglutinina
EP2090648A1 (en) * 2008-02-12 2009-08-19 Institut Francais de Recherche pour l'Exploitation de la Mere(Ifremer) Production of glycosylated polypeptides in microalgae
US7794714B2 (en) * 2008-03-14 2010-09-14 The United States Of America As Represented By The Secretary Of Agriculture Newcastle disease virus monoclonal antibodies
EP3542815A1 (en) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
EP4130273B1 (en) * 2009-12-28 2024-06-12 Sanofi Vaccine Technologies, S.A.S. Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
US9012197B2 (en) * 2009-12-28 2015-04-21 Merial, Inc. Production of hemagglutinin-neuraminidase protein in microalgae

Also Published As

Publication number Publication date
MX351643B (es) 2017-10-23
JP2013515747A (ja) 2013-05-09
KR20120101572A (ko) 2012-09-13
US10633667B2 (en) 2020-04-28
AR079767A1 (es) 2012-02-15
CA2785653C (en) 2018-05-01
AR122325A2 (es) 2022-08-31
US20110162115A1 (en) 2011-06-30
WO2011090708A3 (en) 2011-12-15
CA2785653A1 (en) 2011-07-28
DOP2012000187A (es) 2012-12-15
EP2519258A2 (en) 2012-11-07
CN103260643A (zh) 2013-08-21
EP2519258B1 (en) 2017-07-26
WO2011090708A2 (en) 2011-07-28
EP3213766A1 (en) 2017-09-06
MX2012007545A (es) 2012-11-12
JP5933451B2 (ja) 2016-06-08

Similar Documents

Publication Publication Date Title
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
ES2541217T3 (es) Diferenciación de células madre mesenquimales
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
MX2015013065A (es) Proteinas f de rsv de prefusion y su uso.
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
MX2018007860A (es) Vacunas recombinantes contra el zika.
PH12012500849A1 (en) Mycobacterial vaccines
DK1968632T3 (da) Forbedret influenzavaccine
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
AR092712A1 (es) Una proteina con actividad cetosa 3-epimerasa
UA110806C2 (uk) Мікобактеріальна антигенна композиція
AR061894A1 (es) Vacunas para malaria
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
FI3564378T3 (fi) Immunogeeninen koostumus
PL396415A1 (pl) Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciala specyficznie rozpoznajace bialko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
AR087749A1 (es) Anticuerpos anti-xcr1 humano
AR102410A1 (es) Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa
CL2020002373A1 (es) Composición de vacuna que comprende un péptido aislado de piojo de mar; uso de la vacuna para para prevenir o controlar una infestación de piojos de mar en un salmónido; vector; célula hospedadora (divisional de la solicitud no. 201900422).
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CO2021005069A2 (es) Vacuna de ibv h52 con proteína espicular heteróloga
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina

Legal Events

Date Code Title Description
FC Refusal